Fig. 5

A ROS/cell % over control (n = 12). The experiments were repeated for three times. B Representative image of western blot assay for COX4 in GCs untreated (CTRL), treated with 10µM BCA or with BCA and TAS2R antagonist SBA, CITRO e PRO (n = 5). Band intensity, normalized to Ponceau staining, is reported as fold change relative to the control group. C Immunofluorescence detection of COX4 visualized in green and β-Tubulin (red) in GCs untreated (Ctrl), treated with 10µM BCA or with BCA and TAS2R antagonist SBA, CITRO e PRO (n = 10). DAPI nuclear staining in blue. Scale bars represent 25 𝜇m